Ken Mulvany Ken Mulvany is an entrepreneur and healthcare industry veteran and brings more than 15 years of business leadership and experience to The Cure Parkinson’s Trust. Ken was previously CEO of Proximagen, a UK-based biotech company committed to delivering novel drugs and innovative new treatments for central nervous system (CNS) disorders. Proximagen was acquired in August 2012 by Upsher-Smith Laboratories, Inc. in the US where this pipeline of CNS programmes continues to be advanced. During his time leading Proximagen, Ken was able to secure partnerships and grant funding from a variety of sources including Boehringer-Ingelheim and The Michael J. Fox Foundation in order to advance the company’s novel drug pipeline. Ken has played key roles in developing several successful high-tech businesses particularly with support in raising funding.